|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E differentiates the recurrence risk of PTMC, particularly low-risk PTMC.
|
31790974 |
2020 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF mutation of p.V600E was statistically associated with PTMC with a <i>D</i><sub>max</sub> larger than 5 mm.
|
30915113 |
2019 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Herein we review the present knowledge concerning mPTC's genetic profile, namely the prevalence of BRAF (V600E), RAS and TERT promoter mutations and RET/PTC and PAX8-PPARG rearrangements and report the results of the evaluation in the putative prognostic value of these genetic alterations in mPTC.
|
28659720 |
2017 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A meta-analysis of 2247 PTMC patients revealed that patients with a BRAF(V600E) mutation had a higher likelihood for recurrence (odds ratio 2.09 [confidence interval 1.31-3.33], p = 0.002).
|
26671072 |
2016 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
|
26338373 |
2015 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was detected in 78 of the 113 pT1aNo-x patients (69·0%).
|
24354346 |
2014 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
|
23682579 |
2013 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation is not significantly associated with prognostic factors in PTMC.
|
24228637 |
2013 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
|
23192956 |
2013 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study suggests that highly aggressive PTMCs may arise in a subset of patients with BRAF(V600E) mutation and tumors greater than 5 mm.
|
23370668 |
2013 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation was more frequent in classic (75%), tall cell (91%), and other variants (>70%) than in follicular variant (21%) of papillary thyroid microcarcinoma.
|
22918165 |
2013 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We assessed the T1799A BRAF mutation status in FNAB specimens obtained from all PTMC patients before undergoing total thyroidectomy (TT) and central lymph node dissection (CLND) for PTMC.
|
22799316 |
2012 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We assessed the T1799A BRAF mutation status in FNAB specimens obtained from 61 PTMC patients before undergoing operations for PTMC.
|
20953721 |
2010 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The preval</span>ence of BRAF(V600E</span>) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior.
|
19034577 |
2009 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation can be used as a potential prognostic factor in PTMC patients in a BRAF(V600E)-prevalent area.
|
19710001 |
2009 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types of thyroid tumours.
|
16268813 |
2005 |